• BTC $7,937.11 (-2.46%)
  • ETH $250.48 (-3.44%)
  • MARKET CAP $246B
  • ICOs 4,218

CuraToken

ENDED 13334 views
9.1
Total Rate

Improving Healthcare, Reducing Costs, Saving Lives

CuraServe™ is a complete healthcare ecosystem that improves drug adherence and brings game-changing benefits to patients and healthcare providers. We use a series of outreach tools and messages, supported by predictive modeling and behavioral analytics, to increase the rate of drug adherence. As our CuraServe™ solution helps patients, it’s also generating a vast amount of patient data. That data is then anonymized and made available through CuraData™. The only way that pharmaceutical companies, academics and researchers can access this data by purchasing CuraTokens™. Our data is the first-of-its-kind insight into real-time patient behavior and adherence. CuraData™ will finally give the health and pharmaceutical industries the tools they have been looking for to bring about the change patients need. Our value-based approach to a simple, accessible, yet valuable exchange of data and analysis will revolutionize healthcare. Healthcare is changing forever and CuraServe™ stands at the cutting edge of this transformation. Curaizon™ is the UK-based company that has developed CuraServe™.
General
Website: Visit
White paper: Read
Bounty: Bounty
MVP: View
Pre-sale Time: 31 Aug, 2018 - 1 Nov, 2018
ICO Time: 1 Nov, 2018 - 30 Nov, 2018
Whitelist/KYC: Kyc
Country: UK
Token Info
Ticker: CTKN
Token type: Utlity
Available for sale: 250,000,000 CTKN (50%)
Financial
Pre-sale Price: $0.20
ICO Price: $0.20
Soft cap: 1000000
Hard cap: 25000000
Social Media
  • 1

    CuraServe™ Development Begins

    January 2016 - Curaizon™ begins development of drug-adherence technologies. Development of CuraServe™ begins in collaboration with Gateway Technolabs.

  • 2

    UK Demonstration

    January 2017 - CuraServe™ demonstrated to National Health Service

  • 3

    CuraServe™ Testing

    June 2017 - Internal testing & Review

  • 4

    CuraServe™ Dashboard Creation

    October 2017 - For patients, providers and health services

  • 5

    Token Offering Preparation

    November 2017 - Offering preparation begins

  • 6

    Launch CuraData™ Alpha

    February 2018 - First phase of CuraData™ available

  • 7

    Token Pre-Sale

    August 1st 2018 -

  • 8

    Public token sale

    November 2018 -

  • 9

    Launch CuraData™ Beta

    November 2018 - Live integration with Curaizon's™ data

  • 10

    CuraData™ official release

    February 2019 - Commercialization of platform offering full access to our big data and advanced analytics

  • 11

    Curaizon™ completes clinical trials and launches CuraServe™

    March 2019 - Curaizon’s adherence technology, CuraServe™, is made available to national health services

  • 12

    Roll out to key EU, ME & Commonwealth markets

    April 2019 - Curaizon™ rolls out its adherence technologies to target markets, gaining traction creating mass data

  • 13

    CuraData™ platform experiences huge growth

    July 2019 - As the user-base increases, our data dramatically expands and matures, providing significant growth in value

  • 14

    CuraData™ 2.0

    2020 - Fully integrated and full feature data trading and collaboration platform with patent numbers estimated 90+ million

We’re revolutionizing healthcare and improving drug-adherence through big data analytics delivered via the blockchain.

Problem

Medicines are our most cost‐effective health intervention and represent the first line of defense against chronic and long‐term conditions. Unfortunately, far too many people fail to take their medications properly and the resulting personal and financial costs are staggering. Despite a worldwide recognition of the seriousness of the issue (also called drug non‐adherence), there has been no significant change for the last 30 years.

• Worldwide drug non‐adherence results in approximately $700 billion in additional healthcare costs.

• Pharmaceutical companies lose more than $630 billion in revenue annually to patient non‐adherence and the amount lost is increasing by 13% per year.

Solution

CuraServe™ is a complete healthcare ecosystem that improves drug adherence and brings game‐changing benefits to patients and healthcare providers. We use a series of outreach tools and messages, supported by predictive modeling and

behavioral analytics, to increase the rate of drug adherence. As our CuraServe™

solution helps patients, it’s also generating a vast amount of patient data. That data is then anonymized and made available through CuraData™. The only way that pharmaceutical companies, academics and researchers can access this data by purchasing CuraTokens™. Our data is the first‐of‐its‐kind insight into real‐time patient behavior and adherence. CuraData™ will finally give the health and

pharmaceutical industries the tools they have been looking for to bring about the change patients need. Our value‐based approach to a simple, accessible, yet

valuable exchange of data and analysis will revolutionize healthcare.

Healthcare is changing forever and CuraServe™ stands at the cutting edge of this transformation. Curaizon™ is the UK‐based company that has developed CuraServe™.

Market

The total number of potential users of our platform include all of the patients covered by national health services across the world. This is a total of 1.4 Billion people and growing.

Societal Benefits

• Better Patient Outcomes

• Better Research

• Better Healthcare

• Money Saved

Projected revenue of $800+M and net profit of $660+M in year-3

Nicholas James Rumble

CEO

Chris Matey

COO

Darran Trute

CTO

Mark Nathan

CFO

Luke Lerdal

CDO

Allen Wazny

Head Of Investor Relations

Kristaps Kuhalskis

Creative Director

Pencho Gavazov

Director of Business Development

Dr. Rory McCrea

Chief Advisor

Sarah Chilvers

Clinical Advisor

Put this code to your website

Width: 420px-Height: 210px
comments powered by Disqus
Hot and trending ICOs
This website is using cookies. More info.